Why Moderna (MRNA) stock is trading lower after leaked Phase 3 cancer vaccine data
FROM THE WIRE · FINANCE.YAHOO.COM
What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its personalized cancer vaccine leaked ahead of a planned presentation this weekend, and the stock sold off hard even though the…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishModerna shares sold off sharply on the leak, even though the results themselves look positive.AI-generated summary
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Moderna, Inc.202.63 USDMarket closedtoday -17.57%Negative Merck & Co., Inc.147.24 USDMarket closedtoday -1.76%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets